| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 3,618 | 2,682 | 110,310 | 345,686 |
| Cost of sales | 8,356 | 18,221 | 45,118 | 196,919 |
| Gross profit (loss) | -4,738 | -15,539 | 65,192 | 148,767 |
| General and administrative | 2,613,075 | 1,875,655 | 1,828,200 | 1,582,671 |
| Operations, research and development | 528,557 | 499,715 | 520,406 | 633,422 |
| Sales and marketing | 133,494 | 268,959 | 3,633 | 246,650 |
| Total operating expenses | 3,275,126 | 2,644,329 | 2,352,239 | 2,462,743 |
| Total operating (loss) | -3,279,864 | -2,659,868 | -2,287,047 | -2,313,976 |
| Other income | 2,631 | 682,424 | 3,428 | 36,378 |
| Other expense | 3,504 | 1,451 | 1,797 | 5,822 |
| Gain (loss) on derivative instruments | -74,366,000 | 0 | - | 7 |
| Loss from continuing operations | -77,646,737 | -1,978,895 | -2,285,416 | -2,283,413 |
| Loss from discontinued operations | -5,106 | -91,567 | -157,457 | -811,277 |
| Net (loss) | -77,651,843 | -2,070,462 | -2,442,873 | -3,094,690 |
| Net (loss) per common share, basic and diluted (in dollars per share) | -107.25 | -0.23 | -0.34 | -0.48 |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 723,998 | 9,108,984 | 7,152,221 | 6,396,221 |
| Weighted average shares used in computation basic and diluted (in shares) | 723,998 | 9,108,984 | 7,152,221 | 6,396,221 |
Predictive Oncology Inc. (POAI)
Predictive Oncology Inc. (POAI)